Skip to main content

This website is intended for use by US residents only.

Prescribing Information location icon US healthcare professionals website
CRYSVITA® (burosumab-twza) injection 10, 20, 30 mg/mL

CRYSVITA treats

FIND A SPECIALIST STAY INFORMED
A heart with a plus sign in the middle

Staying on CRYSVITA as prescribed is important for treating XLH

Because XLH is lifelong and progressive, it can continue to affect bones and muscles over time.

We understand that keeping up with a dosing schedule for CRYSVITA can be tough. But when taken as prescribed, CRYSVITA can help keep phosphorus levels in the blood within the normal range. That’s why it is important that you or your child keep going to appointments and stick to the CRYSVITA dosing schedule.

Make sure to discuss strategies with the doctor for sticking with the treatment routine so you can keep your or your child’s treatment on track.

Plan for life’s changes to help continue with CRYSVITA

Some life changes are bigger than others, especially during transitional stages of life. But with some preparation, these changes don’t have to feel so overwhelming.

These changes can include:

  • Moving to a new town
  • Going to college
  • Changing insurance providers

If you or your child have to change doctors for any reason, it’s important to:

  • Ask your current healthcare provider for help identifying another doctor who can continue to provide CRYSVITA
  • Discuss your or your child’s XLH treatment goals
  • Have a conversation with your new doctor about what is—and isn’t—working with the XLH treatment
A calendar date with a star in the middle

This information doesn’t replace talking with your doctor. Be sure to ask them about CRYSVITA and whether it’s right for you.

Kyowa Kirin Cares is committed to helping you or your child stay on CRYSVITA throughout the treatment journey

The Kyowa Kirin Cares Case Manager can help you figure out coverage during life changes, like when switching doctors or insurance providers.

Be sure to reach out to the Kyowa Kirin Cares Case Manager when facing changes that might cause an interruption in CRYSVITA treatment.

Call 833-KK-CARES (833-552-2737) Monday through Friday, 8 AM to 8 PM (ET), or visit Kyowa Kirin Cares to learn more.

Kyowa Kirin Cares Case Managers are only available to patients prescribed certain Kyowa Kirin products. They are not part of your treatment team and do not provide medical advice, nursing, or case management services. Patients should always consult their healthcare provider regarding medical decisions or treatment.

A woman smiling at her desk with a headset on

Actor portrayal

Access helpful resources to support the CRYSVITA
treatment journey for XLH

A pamphlet XLH resources
Three people XLH communities & networks
Two speech bubbles Frequently asked questions
Indication
What is CRYSVITA?

CRYSVITA is a prescription medicine used to treat adults and children 6 months of age and older with X-linked hypophosphatemia (XLH).

read more
What is CRYSVITA?

CRYSVITA is a prescription medicine used to treat adults and children 6 months of age and older with X-linked hypophosphatemia (XLH).

Important Safety Information

You should not take CRYSVITA if:

  • You take an oral phosphate supplement and/or a specific form of vitamin D supplement (such as calcitriol, paricalcitol, doxercalciferol, calcifediol).
  • Your phosphorus levels from a blood sample are within or above the normal range for age.
  • You have kidney problems.

What is the most important information you should know about CRYSVITA?

  • Some patients developed allergic reactions (e.g., rash and hives) while taking CRYSVITA. Your doctor will monitor you for symptoms of an allergic reaction while you are taking CRYSVITA. Your treatment may need to be discontinued for serious allergic reactions.
  • High levels of phosphorus in the blood have been reported in some patients taking CRYSVITA. This may be related to a risk of high calcium levels in the kidneys. Your doctor will collect blood samples to monitor your levels. If you are already taking CRYSVITA, dose interruption and/or dose reduction may be required based on your serum phosphorus levels.
  • High levels of calcium in the blood have been reported in patients taking CRYSVITA. The risk is greater in patients with pre-existing hyperparathyroidism (overactive parathyroid glands), for those who are unable to move for extended periods of time, become dehydrated, have high vitamin D levels, or have kidney issues. If you are at greater risk, your doctor will monitor your blood calcium and parathyroid hormone levels before you start and while taking CRYSVITA. If you develop high levels of blood calcium, your doctor may need to stop your treatment until it is adequately managed.
  • Administration of CRYSVITA may result in reactions at the injection site, such as hives, reddening of the skin, rash, swelling, bruising, pain, severe itching of the skin, and collection of blood outside of a blood vessel (i.e., hematoma). Call your doctor if you develop an injection site reaction. CRYSVITA may be discontinued if severe injection site reactions occur.

What are the possible side effects of CRYSVITA?

  • Adverse reactions that were seen in children with XLH are:
  • Fever
  • Injection site reaction
  • Cough
  • Vomiting
  • Pain in arms and legs
  • Headache
  • Tooth abscess
  • Dental cavities
  • Diarrhea
  • Decreased vitamin D levels
  • Toothache
  • Constipation
  • Muscle pain
  • Rash
  • Dizziness
  • Nausea
  • Adverse reactions that were seen in adults with XLH are:
  • Back pain
  • Headache
  • Tooth infection
  • Restless legs syndrome
  • Decreased vitamin D levels
  • Dizziness
  • Constipation
  • Muscle spasms
  • Phosphorus levels increased in the blood
  • Narrowing of the spaces within the spine is common in adults with XLH, and pressure on the spinal cord has been reported in adults taking CRYSVITA. It is not known if taking CRYSVITA worsens the narrowing of the spaces within the spine or the pressure on the spinal cord.

Before taking CRYSVITA, tell your doctor about all of your medications (including supplements) and medical conditions, including if you:

  • Are taking oral phosphate and/or active vitamin D (such as calcitriol, paricalcitol, doxercalciferol, calcifediol).
  • Are pregnant, think you may be pregnant, or plan to become pregnant. There is not enough experience to know if CRYSVITA may harm your unborn baby. Report pregnancies to the Kyowa Kirin, Inc. Adverse Event reporting line at 1-844-768-3544.
  • Are breastfeeding or plan to breastfeed. There is not enough experience to know if CRYSVITA passes into your breast milk. Talk with your doctor about the best way to feed your baby while you receive CRYSVITA.

While taking CRYSVITA, tell your doctor if you experience:

  • An allergic reaction such as rash or hives
  • A rash, swelling, bruising, or other reaction at the injection site
  • New or worsening restless legs syndrome

These are not all the possible side effects of CRYSVITA. Call your doctor for medical advice about side effects.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Kyowa Kirin, Inc. at 1-844-768-3544.

For important risk and use information, please see the full Prescribing Information for CRYSVITA.

What is CRYSVITA?

CRYSVITA is a prescription medicine used to treat adults and children 6 months of age and older with X-linked hypophosphatemia (XLH).

Important Safety Information

You should not take CRYSVITA if:

  • You take an oral phosphate supplement and/or a specific form of vitamin D supplement (such as calcitriol, paricalcitol, doxercalciferol, calcifediol).
  • Your phosphorus levels from a blood sample are within or above the normal range for age.
  • You have kidney problems.

What is the most important information you should know about CRYSVITA?

  • Some patients developed allergic reactions (e.g., rash and hives) while taking CRYSVITA. Your doctor will monitor you for symptoms of an allergic reaction while you are taking CRYSVITA. Your treatment may need to be discontinued for serious allergic reactions.
  • High levels of phosphorus in the blood have been reported in some patients taking CRYSVITA. This may be related to a risk of high calcium levels in the kidneys. Your doctor will collect blood samples to monitor your levels. If you are already taking CRYSVITA, dose interruption and/or dose reduction may be required based on your serum phosphorus levels.
  • High levels of calcium in the blood have been reported in patients taking CRYSVITA. The risk is greater in patients with pre-existing hyperparathyroidism (overactive parathyroid glands), for those who are unable to move for extended periods of time, become dehydrated, have high vitamin D levels, or have kidney issues. If you are at greater risk, your doctor will monitor your blood calcium and parathyroid hormone levels before you start and while taking CRYSVITA. If you develop high levels of blood calcium, your doctor may need to stop your treatment until it is adequately managed.
  • Administration of CRYSVITA may result in reactions at the injection site, such as hives, reddening of the skin, rash, swelling, bruising, pain, severe itching of the skin, and collection of blood outside of a blood vessel (i.e., hematoma). Call your doctor if you develop an injection site reaction. CRYSVITA may be discontinued if severe injection site reactions occur.

What are the possible side effects of CRYSVITA?

  • Adverse reactions that were seen in children with XLH are:
  • Fever
  • Injection site reaction
  • Cough
  • Vomiting
  • Pain in arms and legs
  • Headache
  • Tooth abscess
  • Dental cavities
  • Diarrhea
  • Decreased vitamin D levels
  • Toothache
  • Constipation
  • Muscle pain
  • Rash
  • Dizziness
  • Nausea
  • Adverse reactions that were seen in adults with XLH are:
  • Back pain
  • Headache
  • Tooth infection
  • Restless legs syndrome
  • Decreased vitamin D levels
  • Dizziness
  • Constipation
  • Muscle spasms
  • Phosphorus levels increased in the blood
  • Narrowing of the spaces within the spine is common in adults with XLH, and pressure on the spinal cord has been reported in adults taking CRYSVITA. It is not known if taking CRYSVITA worsens the narrowing of the spaces within the spine or the pressure on the spinal cord.

Before taking CRYSVITA, tell your doctor about all of your medications (including supplements) and medical conditions, including if you:

  • Are taking oral phosphate and/or active vitamin D (such as calcitriol, paricalcitol, doxercalciferol, calcifediol).
  • Are pregnant, think you may be pregnant, or plan to become pregnant. There is not enough experience to know if CRYSVITA may harm your unborn baby. Report pregnancies to the Kyowa Kirin, Inc. Adverse Event reporting line at 1-844-768-3544.
  • Are breastfeeding or plan to breastfeed. There is not enough experience to know if CRYSVITA passes into your breast milk. Talk with your doctor about the best way to feed your baby while you receive CRYSVITA.

While taking CRYSVITA, tell your doctor if you experience:

  • An allergic reaction such as rash or hives
  • A rash, swelling, bruising, or other reaction at the injection site
  • New or worsening restless legs syndrome

These are not all the possible side effects of CRYSVITA. Call your doctor for medical advice about side effects.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Kyowa Kirin, Inc. at 1-844-768-3544.

For important risk and use information, please see the full Prescribing Information for CRYSVITA.

Go to top button

Back to top

COMM-US-CRY-0929 June 2026